JP7366002B2 - カルバモイルフェニルアラニノール類縁体およびその使用 - Google Patents

カルバモイルフェニルアラニノール類縁体およびその使用 Download PDF

Info

Publication number
JP7366002B2
JP7366002B2 JP2020505344A JP2020505344A JP7366002B2 JP 7366002 B2 JP7366002 B2 JP 7366002B2 JP 2020505344 A JP2020505344 A JP 2020505344A JP 2020505344 A JP2020505344 A JP 2020505344A JP 7366002 B2 JP7366002 B2 JP 7366002B2
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530837A5 (enExample
JP2020530837A (ja
Inventor
ハーレー，フィオン
Original Assignee
ジャズ ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ ファーマシューティカルズ アイルランド リミテッド filed Critical ジャズ ファーマシューティカルズ アイルランド リミテッド
Publication of JP2020530837A publication Critical patent/JP2020530837A/ja
Publication of JP2020530837A5 publication Critical patent/JP2020530837A5/ja
Priority to JP2023072520A priority Critical patent/JP7642707B2/ja
Application granted granted Critical
Publication of JP7366002B2 publication Critical patent/JP7366002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020505344A 2017-07-31 2018-07-31 カルバモイルフェニルアラニノール類縁体およびその使用 Active JP7366002B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072520A JP7642707B2 (ja) 2017-07-31 2023-04-26 カルバモイルフェニルアラニノール類縁体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539088P 2017-07-31 2017-07-31
US62/539,088 2017-07-31
PCT/US2018/044465 WO2019027941A1 (en) 2017-07-31 2018-07-31 CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072520A Division JP7642707B2 (ja) 2017-07-31 2023-04-26 カルバモイルフェニルアラニノール類縁体およびその使用

Publications (3)

Publication Number Publication Date
JP2020530837A JP2020530837A (ja) 2020-10-29
JP2020530837A5 JP2020530837A5 (enExample) 2021-07-26
JP7366002B2 true JP7366002B2 (ja) 2023-10-20

Family

ID=65233074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505344A Active JP7366002B2 (ja) 2017-07-31 2018-07-31 カルバモイルフェニルアラニノール類縁体およびその使用
JP2023072520A Active JP7642707B2 (ja) 2017-07-31 2023-04-26 カルバモイルフェニルアラニノール類縁体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072520A Active JP7642707B2 (ja) 2017-07-31 2023-04-26 カルバモイルフェニルアラニノール類縁体およびその使用

Country Status (12)

Country Link
US (3) US11413264B2 (enExample)
EP (1) EP3661911A4 (enExample)
JP (2) JP7366002B2 (enExample)
KR (1) KR102643275B1 (enExample)
CN (1) CN111094238B (enExample)
AU (1) AU2018312328B2 (enExample)
CA (1) CA3071779A1 (enExample)
MX (2) MX2020001146A (enExample)
RU (1) RU2020108634A (enExample)
SA (1) SA520411187B1 (enExample)
SG (1) SG11202000817SA (enExample)
WO (1) WO2019027941A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023100758A (ja) * 2017-07-31 2023-07-19 ジャズ ファーマシューティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール類縁体およびその使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4531833A2 (en) * 2022-06-03 2025-04-09 Axsome Therapeutics Carbamoyl phenylalaninol compounds as taar1 agonists

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044770A1 (en) 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
WO2000064865A1 (en) 1999-04-23 2000-11-02 Solvay Pharmaceuticals B.V. Monomers and oligourea peptidomimetics and process for the prepa ration thereof
JP2002536358A (ja) 1999-02-05 2002-10-29 エス ケー コーポレイション Ｏ−チオカルバモイル−アミノアルカノール化合物、その薬学的に許容可能な塩類及びその製造方法
JP2006524216A (ja) 2003-04-24 2006-10-26 メナリーニ リチェルチェ ソシエタ ペル アチオニ Ｎｋ−２拮抗塩基性線状化合物及びそれらを含む製剤
CN101823987A (zh) 2009-03-06 2010-09-08 中国科学院上海药物研究所 一类新的dpp-ⅳ抑制剂及其制备方法和用途
CN102249833A (zh) 2011-05-27 2011-11-23 中国科学院化学研究所 一种制备手性γ-氨基酸及其衍生物的方法
WO2017007695A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604434B1 (fr) * 1986-09-29 1989-05-19 Inst Nat Sante Rech Med Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) * 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) * 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US5935997A (en) * 1998-01-13 1999-08-10 Yukong Limited O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
EP1264814A1 (en) * 2001-06-08 2002-12-11 Avantium International B.V. Resolving agents based on amines
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
KR100576372B1 (ko) * 2001-08-03 2006-05-03 에스케이 주식회사 Ｏ-티오카바모일-아미노알카놀 화합물, 이의 약학적 허용염 및 제조방법
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
US20150018414A1 (en) 2013-07-12 2015-01-15 Jazz Pharmaceuticals International lll Limited Promotion of Smoking Cessation
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
SG11201903076QA (en) 2016-10-06 2019-05-30 Jazz Pharmaceuticals International Iii Ltd Carbamoyl phenylalaninol compounds and uses therof
RU2020108634A (ru) 2017-07-31 2021-09-02 Джаз Фармасьютикалз Айрлэнд Лимитед Аналоги карбамоилфенилаланинола и способы их применения

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044770A1 (en) 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Substituted phenethylamine derivatives
JP2002536358A (ja) 1999-02-05 2002-10-29 エス ケー コーポレイション Ｏ−チオカルバモイル−アミノアルカノール化合物、その薬学的に許容可能な塩類及びその製造方法
WO2000064865A1 (en) 1999-04-23 2000-11-02 Solvay Pharmaceuticals B.V. Monomers and oligourea peptidomimetics and process for the prepa ration thereof
JP2006524216A (ja) 2003-04-24 2006-10-26 メナリーニ リチェルチェ ソシエタ ペル アチオニ Ｎｋ−２拮抗塩基性線状化合物及びそれらを含む製剤
CN101823987A (zh) 2009-03-06 2010-09-08 中国科学院上海药物研究所 一类新的dpp-ⅳ抑制剂及其制备方法和用途
CN102249833A (zh) 2011-05-27 2011-11-23 中国科学院化学研究所 一种制备手性γ-氨基酸及其衍生物的方法
WO2017007695A1 (en) 2015-07-09 2017-01-12 The Regents Of The University Of California Mu opioid receptor modulators

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
PIPER, James R. et al.，The Use of α-Amino Acids in the Synthesis of Derivatives of 2-Aminoethanethiol as Potential Antiradiation Agents，Journal of Medicinal Chemistry，1966年11月，vol.9, no.6，pp.911-920
REGISTRY（STN）[online]，2004年05月31日，[検索日 2022.03.24]CAS登録番号 687995-04-6
REGISTRY（STN）[online]，2004年07月28日，[検索日 2022.03.24]CAS登録番号 718595-82-5
REGISTRY（STN）[online]，2004年08月25日，[検索日 2022.03.24]CAS登録番号 732233-83-9
REGISTRY（STN）[online]，2004年08月27日，[検索日 2022.03.24]CAS登録番号 733727-20-3
REGISTRY（STN）[online]，2004年09月01日，[検索日 2022.03.24]CAS登録番号 736915-57-4
REGISTRY（STN）[online]，2004年09月27日，[検索日 2022.03.24]CAS登録番号 752969-88-3
REGISTRY（STN）[online]，2004年10月07日，[検索日 2022.03.24]CAS登録番号 757927-89-2
REGISTRY（STN）[online]，2004年10月26日，[検索日 2022.03.24]CAS登録番号 769907-08-6
REGISTRY（STN）[online]，2004年10月29日，[検索日 2022.03.24]CAS登録番号 772325-14-1
REGISTRY（STN）[online]，2004年11月30日，[検索日 2022.03.24]CAS登録番号 790644-78-9
REGISTRY（STN）[online]，2004年12月08日，[検索日 2022.03.24]CAS登録番号 794507-90-7
REGISTRY（STN）[online]，2004年12月08日，[検索日 2022.03.24]CAS登録番号 794507-91-8
SINHA, Manish et al.，Anriplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain，Bioorganic & Medicinal Chemistry，2014年，vol.22 no.14，pp.3573-3586

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023100758A (ja) * 2017-07-31 2023-07-19 ジャズ ファーマシューティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール類縁体およびその使用
JP7642707B2 (ja) 2017-07-31 2025-03-10 ジャズ ファーマシューティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール類縁体およびその使用

Also Published As

Publication number Publication date
US20210093603A1 (en) 2021-04-01
CN111094238A (zh) 2020-05-01
US11413264B2 (en) 2022-08-16
JP2023100758A (ja) 2023-07-19
WO2019027941A1 (en) 2019-02-07
RU2020108634A (ru) 2021-09-02
SG11202000817SA (en) 2020-02-27
US20220401401A1 (en) 2022-12-22
NZ762140A (en) 2024-11-29
AU2018312328B2 (en) 2022-12-15
MX2020001146A (es) 2020-08-20
EP3661911A4 (en) 2021-04-14
CA3071779A1 (en) 2019-02-07
MX2023005484A (es) 2023-05-18
AU2018312328A1 (en) 2020-03-19
JP7642707B2 (ja) 2025-03-10
JP2020530837A (ja) 2020-10-29
RU2020108634A3 (enExample) 2021-11-30
US20250017890A1 (en) 2025-01-16
KR20200045489A (ko) 2020-05-04
KR102643275B1 (ko) 2024-03-04
CN111094238B (zh) 2023-06-09
EP3661911A1 (en) 2020-06-10
SA520411187B1 (ar) 2024-10-17

Similar Documents

Publication Publication Date Title
JP7366002B2 (ja) カルバモイルフェニルアラニノール類縁体およびその使用
US11780805B2 (en) Carbamoyl phenylalaninol compounds and uses thereof
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
JP2019535643A (ja) （ｒ）−２−アミノ−３−フェニルプロピルカルバメートの溶媒和物フォーム
JP2011526620A (ja) プロテアソームモジュレーターとしての窒素複素環誘導体
WO2025104490A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
JP7157769B2 (ja) 鎮痛剤化合物
HK40003964A (en) Carbamoyl phenylalaninol compounds and uses therof
RU2782320C2 (ru) Анальгетические соединения
RU2782320C9 (ru) Анальгетические соединения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231010

R150 Certificate of patent or registration of utility model

Ref document number: 7366002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150